These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30868399)

  • 1. Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer.
    Fukui K; Masumoto N; Shiroma N; Kanou A; Sasada S; Emi A; Kadoya T; Yokozaki M; Arihiro K; Okada M
    Breast Cancer; 2019 Sep; 26(5):573-580. PubMed ID: 30868399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively.
    Kanou A; Masumoto N; Fukui K; Yokozaki M; Sasada S; Emi A; Kadoya T; Arihiro K; Okada M
    J Med Ultrason (2001); 2022 Oct; 49(4):709-717. PubMed ID: 36002708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
    Ingold Heppner B; Untch M; Denkert C; Pfitzner BM; Lederer B; Schmitt W; Eidtmann H; Fasching PA; Tesch H; Solbach C; Rezai M; Zahm DM; Holms F; Glados M; Krabisch P; Heck E; Ober A; Lorenz P; Diebold K; Habeck JO; Loibl S
    Clin Cancer Res; 2016 Dec; 22(23):5747-5754. PubMed ID: 27189162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study.
    Huang J; Chen X; Fei X; Huang O; Wu J; Zhu L; He J; Chen W; Li Y; Shen K
    Cancer Res Treat; 2019 Oct; 51(4):1336-1346. PubMed ID: 30744321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasonography Combined With Contrast-enhanced Ultrasonography Can Predict Lymphocyte-predominant Breast Cancer.
    Fukui K; Masumoto N; Yokoyama E; Kanou A; Yokozaki M; Sasada S; Emi A; Kadoya T; Arihiro K; Okada M
    Cancer Diagn Progn; 2021; 1(4):309-316. PubMed ID: 35403146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis.
    Ohtani H; Mori-Shiraishi K; Nakajima M; Ueki H
    Pathol Int; 2015 Dec; 65(12):644-51. PubMed ID: 26530981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer.
    Kimura Y; Masumoto N; Kanou A; Fukui K; Sasada S; Emi A; Kadoya T; Arihiro K; Okada M
    Surg Oncol; 2022 May; 41():101725. PubMed ID: 35189516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between absolute neutrophil count and lymphocyte-predominant breast cancer.
    Yoon CI; Park S; Cha YJ; Lee HS; Bae SJ; Cha C; Lee DY; Ahn SG; Jeong J
    Breast; 2020 Apr; 50():141-148. PubMed ID: 31607527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
    Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
    Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
    Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
    Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
    Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
    Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M
    Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
    De Angelis C; Nagi C; Hoyt CC; Liu L; Roman K; Wang C; Zheng Y; Veeraraghavan J; Sethunath V; Nuciforo P; Wang T; Tsimelzon A; Mao S; Hilsenbeck SG; Trivedi MV; Cataldo ML; Pavlick A; Wolff AC; Weigelt B; Reis-Filho JS; Prat A; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
    Clin Cancer Res; 2020 Feb; 26(3):738-745. PubMed ID: 31653641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
    Ahn SG; Cha YJ; Bae SJ; Yoon C; Lee HW; Jeong J
    BMC Cancer; 2018 Mar; 18(1):320. PubMed ID: 29573739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
    Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
    Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.
    Inoue H; Horii R; Ito Y; Iwase T; Ohno S; Akiyama F
    Breast Cancer; 2018 May; 25(3):268-274. PubMed ID: 29185202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
    Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
    BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
    Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO
    Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer.
    Criscitiello C; Bagnardi V; Pruneri G; Vingiani A; Esposito A; Rotmensz N; Curigliano G
    Eur J Cancer; 2017 Dec; 87():164-171. PubMed ID: 29154173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.